Could a common drug shield kidneys from protein damage?
NCT ID NCT02343094
First seen Nov 20, 2025 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This study tested whether sodium phenylbutyrate, a drug already used for other conditions, can reduce a marker of kidney injury in people with proteinuric kidney disease. 26 participants took the drug for 14 days. The goal was to see a 50% drop in a urine marker called Lcn2, which signals kidney stress.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hôpital Necker Enfants Malades
Paris, 75015, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sodium phenylbutyrate
What this could lead to
If it works, this could point toward a new treatment to protect kidneys in people with proteinuric kidney disease.
What could go wrong
This is a small, early-phase trial with only 26 participants. It measures a lab marker, not long-term kidney health, so success is uncertain.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.